ACRO’s 6-year survey of member company CROs demonstrates how risk-based approaches are increasingly used in clinical trials.
In early 2025, ACRO conducted its sixth consecutive landscape survey. The following report highlights ACRO’s key findings for the prior year. The purpose the annual survey is to evaluate adoption levels to improve our understanding of how risk-based quality management (RBQM) is being used across the clinical trial industry. As clinical trials running in traditional operating models reach their planned completion and companies are becoming more innovative, the data shows that CROs are increasingly adopting more efficient risk-based approaches.
Download the ACRO RBQM Summary Report for full readout on the latest adoption trends and key takeaways: